TST 010
Alternative Names: TST-010Latest Information Update: 28 Jan 2026
At a glance
- Originator Transcenta Holding
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Regulatory T-lymphocyte inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for preclinical development in Solid-tumours in World (Parenteral)
- 18 Apr 2023 Pharmacodynamics data from a preclinical study in Solid tumours released by Transcenta Holding
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Solid tumors presented at the Annual Meeting of the American Association for Cancer Research (AACR-2023)